Journal
CANCER CELL INTERNATIONAL
Volume 13, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1475-2867-13-13
Keywords
DNA vaccine; Peptide vaccine; Leukemia-associated antigen; Myeloid leukemia; Immunotherapy
Categories
Funding
- National Natural Science Foundation of China [81270604]
- Key Project Foundation of Science and Technology of Guangzhou [2009Z1-E161]
Ask authors/readers for more resources
While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains largely incurable. This observation is likely due to the drug resistance of leukemic cells, which are responsible for disease relapse. Myeloid leukemia vaccines may most likely be beneficial for eradicating minimal residual disease after treatment with chemotherapy or targeted therapy. Several targeted immunotherapies using leukemia vaccines have been heavily investigated in clinical and preclinical trials. This review will focus on peptides and DNA vaccines in the context of myeloid leukemias, and optimal strategies for enhancing the efficacy of vaccines based on myeloid leukemia immunization are also summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available